IMMXImmix Biopharma, Inc.
$9.30+271% 1Y
$9.30
$2.4852 weeks$14.59
IMMX as reported
- Net income
- −$40M
Net income · +73% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$39M
Free cash flow · +190% year on year · trailing twelve months to Q2 2026
- EPS
- −$0.88
EPS · +14% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$40M | +73% | Q2 2026 |
| EPS | −$0.88 | +14% | Q2 2026 |
| ROE | −94% | n/a | Q2 2026 |
| ROA | −50% | n/a | Q2 2026 |
| Free cash flow | −$39M | +190% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Immix Biopharma, Inc. (IMMX) · Net incomeNet incomeImmix Biopharma, Inc. (IMMX)